Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: Past, present and future

Current Opinion in Investigational Drugs

Volumn 2, Issue 7, 2001, Pages 900-906

  Oermann, C M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antioxidant; Antiproteinase; Cystic fibrosis; IL 10; Macrolide; NSAIDs; Steroids; TNF

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; COLCHICINE; CORTICOSTEROID; FLUTICASONE PROPIONATE; GLUTATHIONE; HEPARIN; IBUPROFEN; INTERLEUKIN 10; LEUKOCYTE ELASTASE; LEUKOCYTE ELASTASE INHIBITOR; MACROLIDE; MONTELUKAST; N [1 (1,3 BENZODIOXOL 5 YL)BUTYL] 3,3 DIETHYL 2 [4 [(4 METHYL 1 PIPERAZINYL)CARBONYL]PHENOXY] 4 OXO 1 AZETIDINECARBOXAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PIROXICAM; PLACEBO; PREDNISONE; PROTEINASE INHIBITOR; RETINOL; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; STEROID; TUMOR NECROSIS FACTOR ALPHA; TYLOXAPOL; UNINDEXED DRUG;

ANTHROPOMETRY; ANTIINFLAMMATORY ACTIVITY; CATARACT; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; GROWTH RETARDATION; HOSPITALIZATION; HUMAN; INFLAMMATION; KIDNEY FAILURE; LONG TERM CARE; LUNG DISEASE; LUNG FUNCTION; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ALPHA 1-ANTITRYPSIN; ANDROSTADIENES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CLINICAL TRIALS; CYSTIC FIBROSIS; HUMANS; IBUPROFEN; MACROLIDES; PIROXICAM; PREDNISONE; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; SERINE PROTEINASE INHIBITORS;

EID: 0034920401     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Role of CFTR in airway disease
2. Cystic fibrosis
3. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation
4. Early pulmonary inflammation in infants with cystic fibrosis
5. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis
6. Lower airway inflammation in infants and young children with cystic fibrosis
7. Immunopathogenesis of cystic fibrosis lung disease
8. -/- mice
9. Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology
10. Alternate day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis
11. Long-term alternate day prednisone therapy in cystic fibrosis
12. Oral steroids for cystic fibrosis (Cochrane Review)
13. Risks of alternate-day prednisone in patients with cystic fibrosis
14. A multicenter study of alternate day prednisone in patients with cystic fibrosis
15. The use of anti-inflammatory medications in cystic fibrosis: Trends and physician attitudes
16. Inhaled corticosteroids for cystic fibrosis (Cochrane Review)
17. Chronic Pseudomonas aeruginosa infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: Influence of local steroid treatment
18. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis
19. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis
20. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection
21. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis
22. A double-blind, placebo-controlled study comparing the effects of the inhaled corticosteroid fluticasone propionate 500 μg BID with placebo in adults with cystic fibrosis
23. Is the acquisition of pseudomonads in cystic fibrosis patients increased by the use of inhaled corticosteroids? Unexpected results from a double blind placebo controlled study
24. Corticosteroids and ibuprofen in cystic fibrosis
25. Ibuprofen in children with cystic fibrosis: Pharmacokinetics and adverse effects
26. Effect of high-dose ibuprofen in patients with cystic fibrosis
27. One year's experience with high-dose ibuprofen therapy in CF
28. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis
29. Clinical use of ibuprofen for cystic fibrosis (CF) lung disease: Data from the 1996 CF Foundation National Patient Registry
30. A preliminary study of the effect of anti-inflammatory treatment in cystic fibrosis patients with Pseudomonas aeruginosa lung infection
31. Phagocyte oxidants and nitric oxide in cystic fibrosis: New therapeutic targets?
32. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis
33. Response to oral β-carotene supplementation in patients with cystic fibrosis: A 16-month follow-up study
34. Long-term oral β-carotene supplementation in patients with cystic fibrosis - Effects on antioxidative status and pulmonary function
35. Vitamin E supplementation in cystic fibrosis
36. Plasma vitamin C concentrations in patients with cystic fibrosis: Evidence of associations with lung inflammation
37. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis
38. 1-protease inhibitor) in CF
39. 1-antitrypsin inhibitor deficiency and cystic fibrosis
40. Modulation of airway inflammation in cystic fibrosis: In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor
41. Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity
42. Anti-inflammatory activity of macrolides: A new therapeutic potential?
43. The anti-inflammatory effects of macrolides
44. Erythromycin treatment in diffuse panbronchiolitis
45. Long-term azithromycin may improve lung function in children with cystic fibrosis
46. Effect of chronic azithromycin on lung function in cystic fibrosis
47. Long term effect of macrolide antibiotics improve pulmonary function in cystic fibrosis
48. Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis
49. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis
50. Eicosapentaenoic acid modulates neutrophil leukotriene B4 receptor expression in cystic fibrosis
51. Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis
52. Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: Preliminary observations
53. Interest in colchicine for the treatment of cystic fibrosis patients. Preliminary report
54. Anti-inflammatory gene therapy for cystic fibrosis with a RAAV-IL-10 vector
55. Sendai virus-mediated overexpression of interleukin 10 following pulmonary and intramuscular administration
56. CFF Research January 2001
57. Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum
58. Phase II study of aerosolized tyloxapol in CF subjects with mild to moderate pulmonary disease
59. Antileukotriene therapy in cystic fibrosis
60. Pharmacokinetics and pharmacodynamics of DMP 777, an inhibitor of human neutrophil elastase, in adult cystic fibrosis patients
61. A double blind placebo controlled crossover study of nebulized heparin therapy in adult cystic fibrosis patients
62. CFF Research January 2001
63. Inflammatory cytokines in cystic fibrosis lungs
64. Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8
65. Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection
66. TNF-α and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment
67. TNF inhibitors in the treatment of arthritis
68. Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases
69. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes